IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker

British Journal of Neurosurgery

Volumn 27, Issue 4, 2013, Pages 442-445

  Kurian, K M ^a   Haynes, H R ^a   Crosby, C ^b   Hopkins, K ^c   Williams, M ^b  

^a FRENCHAY HOSPITAL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

Biomarker; Glioma; IDH

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2;

ARTICLE; COMPARATIVE STUDY; DNA DETERMINATION; GENE MUTATION; GENETIC PREDISPOSITION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; MUTATION RATE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

ASTROCYTOMA; CENTRAL NERVOUS SYSTEM NEOPLASMS; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MUTATION; NEOPLASM GRADING; PROGNOSIS; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84881439013     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.3109/02688697.2013.771139     Document Type: Article

References (21)

1. Parsons DW, Jones S, Zhang X, et al. A n integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-12.
2. Balss J, Meyer J, Muller W, et al. A nalysis of the IDH1 codon 132 mutation in brain tumours. Acta Neuropathol 2008; 116: 597-602.
3. Yan H, Parsons DW, Jin G, et al. I DH1 and IDH2 mutations in gliomas. New Engl J Med. 2009; 360: 765-73.
4. Hartmann C, Meyer J, Balss J, et al. T ype and Frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial diff erentiation and age: a study of 1010 diff use gliomas. Acta Neuropathol 2009; 118: 469-74.
5. Nobusawa S, Watanabe P, Kleihues H, Ohgaki H. IDH1 mutations as molecular signature and predictive value of secondary glioblastomas. Clin Cancer Res 2009; 15: 6002-7.
6. Sanson M, Marie Y, Paris S, et al. I socitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150-4.
7. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavourable prognostic eff ect of higher age: implications for classifi cation of gliomas. Acta Neuropathol 2010; 120: 707-18.
8. Kloosterhof N, Bralten LBC, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diff use glioma? Lancet Oncol 2011; 12: 83-91.
9. Ahmadi R, Stockhammer F, Becker N, et al. N o prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol 2012 Epub Ahead of Print.
10. Watanabe T, Nobusawa P, Kleihaus H, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Path 2009; 174: 1149-53.
11. Yan H, Bigner D, Velculescu V, Parsons DW. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 2009; 69: 9157-9.
12. I chimura K, P earson D M, K ocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009; 11: 341-7.
13. Fu Y, Huang R, Du J, et al. G lioma-derived mutations in IDH: From mechanism to potential therapy. Biochem Biophys Res Commun 2010; 397: 127-30.
14. Combs SE, Rieken S, Wick W, et al. Prognostic Signifi cance of IDH1 and MGMT in patients with glioblastoma: one step forward, and one step back. Rad Oncol 2011; 6: 115-9.
15. Kros JM, Gorlia T, Kouwenhoven MC, et al. Panel review of anaplastic oligodendroglioma from European Organisation for Research and Treatment of Cancer Trial. J Neuropathol Exp Neuro 2007; 6: 545-51.
16. Capper D, Weissert S, Balss J, et al. Characterisation of R132H mutation specifi c IDH1 antibody binding in brain tumours. Brain Pathol 2009; 20: 245-54.
17. Weller M, Wick W, von Diemling A. Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas. Glia 2011; 59: 1200-4.
18. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal Antibody specifi c for IDH1 R132H mutation. Acta Neuropathol 2009; 118: 599-601.
19. Gravendeel LA, Kloosterhoof NK, Bralten LB, et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat 2010; 31: E1186-99.
20. G ravendeel L A, K ouwenhoven M C, G evaert O, et al. Intrinsic gene expression profi les of gliomas are a better predictor of survival than histology. Cancer Res 2009; 69: 9065-72.
21. P reusser M, C apper D, H artmann C. I DH testing in diagnostic neuropathology: review and practical guideline article invited by Euro-CNS research committee. Clin Neuropathol 2011; 30: 217-30.